{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:50:59Z","timestamp":1790416259705,"version":"4.1.0"},"reference-count":32,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Incretin-based therapies, particularly glucagon-like peptide-1 receptor agonists (GLP-1 RAs), have emerged as potentially promising therapeutic agents for improving ovarian function, especially in women with polycystic ovary syndrome (PCOS) and obesity-related reproductive dysfunction. This comprehensive review synthesizes evidence from 30 highly relevant studies examining the mechanisms of action, clinical outcomes, and safety profile of incretin therapies on ovarian function. The evidence suggests that GLP-1 RAs may exert beneficial effects through multiple molecular pathways, including FOXO1 signaling, modulation of steroidogenesis, and enhancement of insulin sensitivity, although most mechanistic data derive from animal models and in vitro studies without validation in human ovarian tissue. Clinical outcomes from randomized controlled trials and meta-analyses show improvements in menstrual regularity, hormonal profiles, and spontaneous conception rates, though evidence certainty is limited by small sample sizes, short duration, high heterogeneity, and restriction to overweight\/obese populations. While preliminary safety data regarding inadvertent early pregnancy exposure are reassuring, animal studies suggest potential dose-dependent risks that warrant careful consideration. Importantly, GLP-1 RAs are not currently approved or guideline-recommended for fertility restoration, and substantial uncertainty remains regarding long-term reproductive safety, optimal patient selection, and clinical guidelines. This review provides a balanced synthesis of current evidence and identifies critical gaps requiring further investigation before routine clinical use can be recommended.<\/jats:p>","DOI":"10.3390\/ijms27114752","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T14:10:22Z","timestamp":1779718222000},"page":"4752","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Benefits of Incretin Therapy on Ovarian Function: A Scientific Literature Review"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7113-2372","authenticated-orcid":false,"given":"Sandro","family":"La Vignera","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95124 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5217-9343","authenticated-orcid":false,"given":"Rosita A.","family":"Condorelli","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95124 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1484321","DOI":"10.1155\/2020\/1484321","article-title":"GLP-1\/GLP-1R Signaling Regulates Ovarian PCOS-Associated Granulosa Cells Proliferation and Antiapoptosis by Modification of Forkhead Box Protein O1 Phosphorylation Sites","volume":"2020","author":"Sun","year":"2020","journal-title":"Int. J. Endocrinol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.fertnstert.2018.05.004","article-title":"Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"110","author":"Teede","year":"2018","journal-title":"Fertil. Steril."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"American College of Obstetricians and Gynecologists (2018). ACOG Practice Bulletin No. 194: Polycystic Ovary Syndrome. Obstet. Gynecol., 131, e157\u2013e171.","DOI":"10.1097\/AOG.0000000000002656"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S223","DOI":"10.2337\/dc09-S315","article-title":"Incretin-based therapies: Viewpoints on the way to consensus","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes","volume":"385","author":"Frias","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1210\/er.2011-1034","article-title":"Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications","volume":"33","author":"Dunaif","year":"2012","journal-title":"Endocr. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e2695","DOI":"10.1210\/clinem\/dgaa285","article-title":"Obesity, polycystic ovary syndrome, and infertility: A new avenue for GLP-1 receptor agonists","volume":"105","author":"Cena","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/17446651.2025.2554668","article-title":"Reframing polycystic ovary syndrome as a complication of obesity: The evolving role of incretin-based therapies","volume":"20","author":"Jensterle","year":"2025","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Mukherjee, A.G., Wanjari, U.R., Kannampuzha, S., Murali, R., Namachivayam, A., Ganesan, R., Dey, A., Babu, A., Renu, K., and Vellingiri, B. (2023). The Implication of Mechanistic Approaches and the Role of the Microbiome in Polycystic Ovary Syndrome (PCOS): A Review. Metabolites, 13.","DOI":"10.3390\/metabo13010129"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.55014\/pij.v8i2.794","article-title":"Clinical application and mechanistic investigation of GLP-1 receptor agonists in the treatment of polycystic ovary syndrome","volume":"8","author":"Liu","year":"2025","journal-title":"Pac. Int. J."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Voros, C., Chatzinikolaou, F., Papapanagiotou, I., Polykalas, S., Mavrogianni, D., Koulakmanidis, A.-M., Athanasiou, D., Kanaka, V., Bananis, K., and Athanasiou, A. (2026). A systematic review on GLP-1 receptor agonists in reproductive health: Integrating IVF data, ovarian physiology and molecular mechanisms. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27020759"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1210\/jc.2008-0115","article-title":"Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome","volume":"93","author":"Marrioneaux","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1530\/EJE-13-0797","article-title":"Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin","volume":"170","author":"Sever","year":"2014","journal-title":"Eur. J. Endocrinol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Zhou, Q., Qu, H., Yang, L., and Shou, L. (2023). Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: A meta-analysis and systematic review. BMC Endocr. Disord., 23.","DOI":"10.1186\/s12902-023-01500-5"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-18-0175","article-title":"Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: A pilot randomized study","volume":"179","author":"Salamun","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1210\/clinem\/dgaa852","article-title":"Establishment of a Novel Human Fetal Adrenal Culture Model that Supports de Novo and Manipulated Steroidogenesis","volume":"106","author":"Melau","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s11845-020-02320-5","article-title":"Comparing the effect of sitagliptin and metformin on the oocyte and embryo quality in classic PCOS patients undergoing ICSI","volume":"190","author":"Daneshjou","year":"2021","journal-title":"Ir. J. Med. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.rbmo.2017.03.023","article-title":"Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: A randomized clinical trial","volume":"35","author":"Nylander","year":"2017","journal-title":"Reprod. Biomed. Online"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12958-025-01447-3","article-title":"Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight\/obese women with polycystic ovary syndrome: A prospective, randomized, controlled, open-label clinical trial","volume":"23","author":"Chen","year":"2025","journal-title":"Reprod. Biol. Endocrinol."},{"key":"ref_22","first-page":"2161","article-title":"Liraglutide and polycystic ovary syndrome: Is it only a matter of body weight?","volume":"46","author":"Pugliese","year":"2023","journal-title":"J. Endocrinol. Investig."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Abedi, M.M., Patni, M.M., Shajahan, A.N.B., Dube, R., Khadeeja, L., Alabid, I., Kharoufeh, A., Kar, S.S., George, B.T., and Bahutair, S.N. (2026). GLP-1 Receptor Agonists, Fertility Restoration, and Reproductive Safety in Women of Reproductive Age: A Narrative Review. J. Clin. Med., 15.","DOI":"10.3390\/jcm15093204"},{"key":"ref_24","first-page":"857","article-title":"The role of glucagon-like peptide-1 receptor agonists in the correction of immune and metabolic disorders in women with reproductive dysfunction","volume":"19","author":"Kozhukhov","year":"2025","journal-title":"Obstet. Gynecol. Reprod."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.58779\/issn.2954-467X.tjor2023.v2.n2.27","article-title":"Reproduction and Anti-Obesity Medications: A Review of Current Evidence","volume":"2","year":"2023","journal-title":"J. Reprod."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.18535\/cmhrj.v5i05.511","article-title":"The Ozempic Pregnancy Phenomenon: What Medical Research Reveals","volume":"5","author":"Heimann","year":"2025","journal-title":"Clin. Med. Health Res. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): A double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Olewi, N.Z., and Hassan, A.F. (2026). Possible protective effects of tirzepatide on polycystic ovary syndrome in female rat model induced by testosterone propionate in comparison to metformin. Naunyn-Schmiedeberg\u2019s Arch. Pharmacol.","DOI":"10.1007\/s00210-026-05346-1"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Anala, A.D., Saifudeen, I.S.H., Ibrahim, M., Nanda, M., Naaz, N., and Atkin, S.L. (2023). The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome. J. Clin. Med., 12.","DOI":"10.3390\/jcm12144575"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-Hormone-Receptor Agonist Retatrutide for Obesity\u2014A Phase 2 Trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_32","first-page":"e102358","article-title":"Combined Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) and Sodium-Glucose Cotransporter 2 Inhibitor (SGLT2i) Therapy to Restore Fertility in Patients with Obesity, Polycystic Ovary Syndrome, and Incident Type 2 Diabetes","volume":"18","author":"Banerjee","year":"2026","journal-title":"Cureus"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/11\/4752\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:40:57Z","timestamp":1780548057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/11\/4752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":32,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["ijms27114752"],"URL":"https:\/\/doi.org\/10.3390\/ijms27114752","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]}}}